

Questions for categories:

- **Investment Rational**

We have developed cResponse, a functional drug sensitivity platform to determine individualized patient treatment regimens. Fresh patient cancer samples are sectioned into thick slices which when cultured in cResponse platform demonstrate similar architecture and tissue proliferation to those found in vivo. To validate the capacity of the cResponse platform to predict patient response to cancer treatment, patients with different cancer types receiving diverse chemotherapeutic and targeted agents were recruited to our recent clinical study.

- **Business Strategy**

Preliminary results demonstrated that cResponse could predict the patient's response with high accuracy when compared with the patient's imaging results. The Company is offering its service to oncology patients, enabling meaningful decision support tool to assist in choice of drugs for patients & oncologists. In addition, the company is collaborating with leading global oncology pharmaceutical companies, maximizing the probability of success in their drug discovery and pre-clinical activities.

- **Core Technology**

The high viability of the tissue over an extended period of time allows for a rapid genomic profiling to help prioritize drugs to be tested by cResponse, as well as the capacity to evaluate the effects of slow acting drugs such as targeted therapy.

Product Profile/Pipeline

The Company is offering the service in and from the Israeli lab, opened a lab in London and conducting a multi-center clinical program in the UK with leading cancer sites. In parallel, the company is working on integrating Artificial Intelligence in the assessment of efficacy of various anti-cancer drugs and in obtaining additional information from its' platform,

- **What's Next?**

The integration of this platform in directing anti-cancer treatment may lead to better response rate of cancer patients to therapy. Curesponse is planning to expand to North America, open a lab there and continue demonstrating the value of its' technology to the clinical community.